Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy
- PMID: 21550136
- DOI: 10.1016/j.jaad.2010.08.003
Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy
Abstract
Muir-Torre syndrome (MTS) is an autosomal dominant genodermatosis caused by mutations in the DNA mismatch repair genes MLH1 and MSH2. This case describes a patient with an extensive family history of colon cancer who experienced the onset of multiple sebaceous adenomas and carcinomas after undergoing kidney transplantation and receiving immunosuppressive therapy. The finding of deficient MSH2 expression in the immunohistochemical analysis of a sebaceous carcinoma prompted genetic testing for a systemic mutation in the mismatch repair gene. A systemic mutation of the MSH2 gene was detected and, despite the absence of a visceral malignancy, the diagnosis of MTS was made. Immunosuppression has previously been thought to play a possible role in unmasking a latent MTS phenotype in transplant recipients, but systemic mutations have not previously been analyzed. The relationship between immunosuppression and sebaceous tumors with the possibility of unmasking a MTS phenotype in transplant recipients is discussed.
Copyright © 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
Similar articles
-
Muir-Torre syndrome: sebaceous carcinoma concurrent with colon cancer in a kidney transplant recipient; a case report.BMC Nephrol. 2019 Oct 29;20(1):394. doi: 10.1186/s12882-019-1592-7. BMC Nephrol. 2019. PMID: 31664942 Free PMC article.
-
Muir-Torre syndrome caused by partial duplication of MSH2 gene by Alu-mediated nonhomologous recombination.Br J Dermatol. 2008 Jan;158(1):150-6. doi: 10.1111/j.1365-2133.2007.08233.x. Epub 2007 Oct 17. Br J Dermatol. 2008. PMID: 17941949
-
Patients with a new-onset cutaneous sebaceous neoplasm following immunosuppression should be evaluated for Muir-Torre syndrome with germline mismatch repair gene mutation analysis: case reports.Dermatol Online J. 2024 Mar 15;30(1). doi: 10.5070/D330163287. Dermatol Online J. 2024. PMID: 38762859
-
Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm.J Cutan Pathol. 2009 Jun;36(6):613-9. doi: 10.1111/j.1600-0560.2009.01248.x. J Cutan Pathol. 2009. PMID: 19515040 Review.
-
Different phenotypes in Muir-Torre syndrome: clinical and biomolecular characterization in two Italian families.Br J Dermatol. 2005 Jun;152(6):1335-8. doi: 10.1111/j.1365-2133.2005.06506.x. Br J Dermatol. 2005. PMID: 15949004 Review.
Cited by
-
Muir-Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients.Fam Cancer. 2014 Dec;13(4):553-61. doi: 10.1007/s10689-014-9733-4. Fam Cancer. 2014. PMID: 24969397
-
Diagnostic error: what Muir-Torre syndrome has taught us.BMJ Case Rep. 2015 Mar 20;2015:bcr2014206959. doi: 10.1136/bcr-2014-206959. BMJ Case Rep. 2015. PMID: 25795746 Free PMC article. Review.
-
Case Report: A Frameshift Mutation in MSH2 Exon 2 in a Kidney Recipient With Muir-Torre Syndrome.Front Oncol. 2021 Jun 24;11:681780. doi: 10.3389/fonc.2021.681780. eCollection 2021. Front Oncol. 2021. PMID: 34249727 Free PMC article.
-
More than just skin deep: faciocutaneous clues to genetic syndromes with malignancies.Oncologist. 2012;17(7):930-6. doi: 10.1634/theoncologist.2012-0033. Epub 2012 Jun 15. Oncologist. 2012. PMID: 22707513 Free PMC article. Review.
-
Sebaceous carcinoma in immunosuppressed patients: a narrative review.Arch Dermatol Res. 2025 Jan 6;317(1):172. doi: 10.1007/s00403-024-03710-w. Arch Dermatol Res. 2025. PMID: 39760765 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical